Institut De Recherches Internationales Servier
Clinical trials sponsored by Institut De Recherches Internationales Servier, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets rare gene mutation in Hard-to-Treat blood cancers Results expected Dec 2026 (estimated)
-
New hope for rare MDS: targeted drug ivosidenib takes on standard therapy
Disease control Recruiting nowThis study is for people with a rare form of myelodysplastic syndromes (MDS) that has a specific genetic change called IDH1 mutation. Participants have not had prior treatment with certain drugs. They will be randomly assigned to receive either ivosidenib (a daily pill) or azacit…
Phase 3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for kids with rare epilepsy: first human trial launches
Disease control Recruiting nowThis study tests a new medicine (S230815) for children aged 2-12 with a rare, severe epilepsy caused by changes in the KCNT1 gene. The goal is to see if the drug is safe and can help control seizures. About 20 children will take part, receiving the drug through a spinal injection…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets rare gene mutation in Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests an oral drug called AG-120 in people with advanced blood cancers, like acute myeloid leukemia, that have a specific IDH1 mutation. The study aims to find the safest dose and see if the drug can control the disease. About 291 participants will take the…
Phase 1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare bile duct cancer: targeted combo trial launches
Disease control Recruiting nowThis study tests a new combination of drugs (ivosidenib, durvalumab, and chemotherapy) as a first treatment for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. The goal is to see if the combination is safe and works better than st…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC